Brown Brothers Harriman & Co’s BioSpecifics Technologies Corp. BSTC Stock Holding History

Brown Brothers Harriman & Co’s Portfolio BSTC Stock Details BSTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-73	Closed	-$3K	–	1221
2017 Q4	$3K	Buy	+73	New	+$3.28K	﹤0.01%	996

Other funds holding BSTC

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ECP

Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Brown Brothers Harriman & Co's BSTC Position: Q1 2018 in Review

Brown Brothers Harriman & Co sold out of BioSpecifics Technologies Corp. (BSTC) in Q1 2018, closing a stake of 73 shares — an estimated $3K sold.

Brown Brothers Harriman & Co first reported a position in BSTC in Q4 2017 and held it in 1 quarter. The position peaked at $3K in Q4 2017. 78 funds tracked by Wall St. Rank hold BSTC as of Q1 2018.

Brown Brothers Harriman & Co reported no remaining BioSpecifics Technologies Corp. position as of Q1 2018 after selling out during the quarter.
Brown Brothers Harriman & Co sold 73 BioSpecifics Technologies Corp. shares in Q1 2018, an estimated $3K.
Brown Brothers Harriman & Co first reported a position in BioSpecifics Technologies Corp. in Q4 2017 and held it in 1 quarter.
Brown Brothers Harriman & Co's BioSpecifics Technologies Corp. position peaked at $3K in Q4 2017.
78 funds tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q1 2018.

Based on Brown Brothers Harriman & Co's 13F filing for Q1 2018, filed 14 May 2018.